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Figure S1 Observed ROESY spectra of 6 
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Figure S2 Observed HMBC spectra of 16 
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Comparison of binding affinities between mesembrane and Sceletium tortuosum Zembrin® 
According to Harvey et al., the binding assays was carried out at Cerep in France 
(http://www.cerep.fr/cerep/users/pages/catalog/p_ProfileCatalogue.asp?profile=2118). As we cannot 
access to the web page indicated by the above URL, the assay protocol was not clear. However, Cerep 
shows the protocols of binding assays for the MOR, DOR, and KOR on view (MOR: 
http://www.cerep.fr/cerep/users/pages/catalog/Affiche_CondExp_Test.asp?test=118; DOR: 
http://www.cerep.fr/cerep/users/pages/catalog/Affiche_CondExp_Test.asp?test=114; KOR: 
http://www.cerep.fr/cerep/users/pages/catalog/Affiche_CondExp_Test.asp?test=1971). 
 
Summary of our and Cerep’s protocols was shown in Table S1 and S2. In the Cerep’s protocol, the 
labeled ligands were used at two- or four-fold lower concentration compared with our protocol.  
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Table S1 Our protocol 
 MOR DOR KOR 
source human recombinant human recombinant human recombinant 
labeled ligand [3H] DAMGO [3H] DPDPE [3H] U-69,593 
ligand concentration 2.0 nM 2.0 nM 2.0 nM 
non specific DAMGO (1.0 µM) DPDPE (1.0 µM) U-69,593 (1.0 µM) 
reference 
DAMGO  
(IC50: 4.399 nM) 
DPDPE  
(IC50: 4.889 nM) 
U-69,593  
(IC50: 2.671 nM) 
 
Table S2 Cerep’s protocol 
 MOR DOR KOR 
source human recombinant human recombinant rat recombinant 
labeled ligand [3H] DAMGO [3H] DADLE [3H] U-69,593 
ligand concentration 0.5 nM 0.5 nM 1 nM 
non specific naloxone (10 µM) naltrexone (10 µM) naloxone (10 µM) 
reference 
DAMGO  
(IC50: 0.537 nM) 
DPDPE  
(IC50: 1.8 nM) 
U-50,488  
(IC50: 0.84 nM) 
 
The binding abilities of the tested compounds at 10 µM (the highest concentration of the tested 
compounds) was shown by the not-replaced bindings of the labeled compounds (Table S3). 
 
Table S3 The binding abilities of the tested compounds at 10 µM 
Compound Not-replaced binding (%) 
 MOR DOR KOR 
mesembrane (4)  82.7 92.3 93.0 
13ʹ 40.4 39.8 12.1 
15 82.8 97.8 59.4 
15ʹ 9.4 24.6 3.8 
epi-15ʹ 25.1 84.9 15.1 
 
In the Cerep’s protocol, the labeled ligands and the tested compound were used at lower and extremely 
higher concentration, respectively compared with our protocol. Both factors leads the values of both 
not-replacing binding and IC50 obtained by Cerep’s protocol lower compared with the values obtained 
by our protocol.  
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It is difficult to compare the binding abilities between mesembrane and Sceletium tortuosum Zembrin®, 
but compound 13ʹ, which had the lowest binding affinities among the compounds with phenolic 
hydroxy group, would have higher affinities than did Sceletium tortuosum Zembrin®. 
 
Conformational analyses 
Conformational analyses of protonated compounds 13ʹ, 15ʹ, and epi-15ʹ were carried out. The defined 
dihedral angles are indicated by red arrows (Fig. S3).  
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Figure S3 Chemical structures of protonated compounds 13ʹ, 15ʹ, and epi-15ʹ. The red arrows 
indicates the defined dihedral angles. 
 
The results of the conformational analyses were summarized in Table S4. The most stable conformer 
of these protonated compounds did not necessarily assume the S-configuration at the nitrogen. 
However, taking into account the conformers with higher energy, all the compounds adopted the S-
configuration. 
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Table S4 Energy of the most stable conformer and the number of conformers within 2.5, 3.0, 4.0, 5.0, 
7.5 and 10.0 kcal/mol of the most stable conformer. 
  
most stable  
conformer (kcal/mol) < 2.5 < 3.0 < 4.0 < 5.0 < 7.5 < 10.0 
13ʹ (R) 61.53  0  1 1 1  6  18  
13ʹ (S) 58.55  3  4 7 12  26  36  
15ʹ (R) 55.59  0  0 0 4  6  25  
15ʹ (S) 50.75  8  9 12 15  47  92  
epi-15ʹ (R) 59.66  2  2 3 8  14  25  
epi-15ʹ (S) 65.65  0  0 0 0  2  5  
 
Copies of NMR spectra 
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